Becton Dickinson
BDX (NYSE)
Becton Dickinson (BDX), a medical technology firm recognized for its narrow or wide moat, is currently trading at a discount, presenting an attractive opportunity for value-focused investors. With a 2.28% dividend yield and a recent 1-year return of 21.07%, it showcases solid performance amid a challenging 5-year return of -1.59%. Analysts maintain a median 12-month price target of $168.01, with some projecting an average target of $191.46, indicating potential upside from its current valuation.
Pros:
- Strong position in medical technology
- Diverse product offerings
Cons:
- Market volatility risk
- Recent stock performance fluctuations
Becton Dickinson (BDX) may be a suitable investment for value-focused investors looking for exposure to the medical technology sector, particularly given its current trading discount and solid dividend yield of 2.28%. While the recent 1-year performance is promising, potential investors should consider the mixed long-term returns and weigh their risk tolerance accordingly.